GSK (GlaxoSmithKline)GSK
Recorded

GSK (GlaxoSmithKline) 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration27 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Seamus FernandezAnalyst

Thanks for joining us here at another of Guggenheim's Healthcare Innovation Conferences. We do this annually, and I'm really pleased to have GSK here with us today. For those of you who followed me a couple years ago, you saw how many times I made the mistake of calling GSK GlaxoSmithKline. I'm really pleased to have Dr. Kayvan Khavandi here with us. He's Senior Vice President R&D, Head of Respiratory, Immunology and Inflammation. I think this is a great opportunity for us to talk about GSK's approach to immunology and inflammation at this point. Can you maybe just kind of walk us through how you're thinking about the kind of discovery, development across the specialty R&D portfolio? Then, maybe just give us a little bit more information about your role, and how you're approaching the opportunity to accelerate the growth strategy at GSK.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

Great. Thanks for having me here, Seamus. I'm head of, as Seamus described, an end-to-end R&D unit that covers all non-oncology and non-vaccines ID product discovery and development. I also lead another organization in GSK that's called Translational and Development Sciences, which is really focused on where we derive the highest human causal confidence to decide what we want to advance into early clinical developments and how to prosecute that in the context of complex human disease. That's a good segue to answer your question, which is, as an industry, I think we've moved away from the chronology of do some biology, then decide if it's relevant to humans, then have a handoff where you put a clinical development hat on and you start to think about trial design and what patient phenotypes you want to study. We're reverse translating, where you start off with those questions.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

What mechanisms do you want to deploy into disease state-specific settings? That's really important when you think about the diseases that I'm focused on, which are chronic obstructive pulmonary disease, metabolic dysfunction-associated steatohepatitis, pulmonary hypertension, chronic kidney disease. These are complex, chronic inflammatory diseases which are heterogeneous and typically present with multi-morbid risk. Almost none of those diseases present with an isolated end organ dysfunction that's distinct from a system that's perturbed. When we think about discovery, we're increasingly thinking about discovery through translation. The acid test for that is when you start to think about target identification, immediately think about what the phase II proof of concept study is. That's a natural force function to accelerate, because sometimes it means, "Actually, I don't need to do five years of biology.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

I've got what I need, and I can test this clinically." Instead, the most material enabler for the program to progress is identification of a biomarker that identifies the responder population. So doing these things by design and by prediction rather than empirically and retrospectively.

Seamus FernandezAnalyst

Okay. I am going to jump right out into it. What do you think is the most underappreciated asset in terms of the, where the street is maybe just not paying attention, or that you are particularly excited about within the RI&I portfolio?

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

I will start off with a disease area, which is chronic obstructive pulmonary disease.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

Yeah. You hear these stats, but I am not sure that they ever really sink in when you think about the fact that 400 million people globally are affected, third biggest killer.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

It is not a good premature mortality. It follows an increasing degree of morbidity, burden on healthcare systems, and we are really in the infancy of targeted therapy. There are two approved biologics for a prevalent fatal disease. We focused very significantly on obstructive respiratory disorders, including COPD, but also non-CF bronchiectasis, which obviously we have seen now with the first approved therapy is tractable and can generate significant value, but still has huge unmet needs.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

We see COPD as an area that is probably underappreciated, and then we have a true portfolio strategy where we have used data, technology, and experience to partition out what are the distinct drivers of risk in different subtypes of COPD, and we have a solution across those. Within that, then if you think about the IL-33 mechanism, we have what we believe to be a best-in-class approach with a long-acting profile, but actually, we really telegraphed what ended up happening with the class by initiating a study in non-CF bronchiectasis.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

Which is not a Th2-driven eosinophilic disease. It is a disease that is defined by mucus plugging, airway remodeling, typically in non-smokers. That is currently in phase II, which we will read out alongside with our phase III initiation in COPD. One study of which, very excitingly, we have announced will include a cardiopulmonary outcome study. Patients with COPD have exacerbations. Those exacerbations are prognostically important. They predict cardiovascular all-cause mortality. We are looking forward to generating what would be the pivotal study with the most hard endpoints evidence in support of a product.

Seamus FernandezAnalyst

Great. You mentioned IL-33, but the programs that you and the team have had responsibility for include, on market, depemokimab now, and the long-acting TSLP. It is very clear that GSK is taking a concerted view that long-acting assets may in fact be the path forward for immunologic disorders at a minimum. Can you talk a little bit about that, and is that just a commercial angle, or what does it mean in terms of the actual disease state?

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

We started off with ultra-long-acting, as you said, with Exdensur and asthma. If you think about asthma, we have got to a point in terms of targeted medicine profiles and efficacy effect sizes, which are very, very good. If you look at the Exdensur SWIFT data, over 50% annualized exacerbation reduction. In some regions that might be more pure, uncontrolled populations, efficacy gets up to 80%, 90%. I think we are naturally reaching a ceiling or diminishing return in terms of both the likelihood of having a product that has got greater efficacy in an RCT, but also, frankly, the operating characteristics of the trial endpoints to even demonstrate and tease out those differences, even if the biological truth is there.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

We call ultra-long-acting pragmatic innovation, which is in a disease where most patients come off drug by a year, which is the case with asthma, and only a third of the population initiates a biologic, what is the way in which you can most readily transform care? That is to introduce a solution where patients persist. They therefore have sustained benefit from the types of clinical measures we study in trials, which are spirometry, exacerbation reduction, PROs, but actually the community is moving towards concepts of remission, and you can only achieve remission if you stay on the drug long enough.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

Yeah. We think ultra-long-acting in asthma is absolutely critical and where we've obviously invested in terms of the next wave.

Kaivan KhavandiSVP, R&D, and Head of Respiratory, Immunology and Inflammation

COPD requires more mechanistic innovation, but of course, all those attributes of the long-acting are important. In COPD, if you have a single exacerbation, your entire disease trajectory could change, and you could die on that admission, of course.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day